Tag Archives: investment banking

Analyst: Biotech to Have ‘Eventful Year’ with Data Readouts in Three Indications

Sourced from: https://www.countingpips.com/2019/03/analyst-biotech-to-have-eventful-year-with-data-readouts-in-three-indications/

Also in the report, Arce temporarily outlined DURECT’s Q4/18 financials, suggesting revenue during the quarter was $3.6 million. At 2018, the company had $34.5 million in cash and cash equivalents, along with $20.5 million of money from a term loan.

Part A registration of average AH patients for your 90 mg dose continues. Both components could advance to the final 150 mg dose if the dose escalation committee decides the safety and pharmacokinetic profiles are adequate.

Psoriasis is your second sign for which DUR-928 data will be forthcoming. DURECT has scheduled enrollment for the Stage 2a proof-of-concept trial of topical DUR-928 for mild to moderate plaque psoriasis to begin at the end of the month. This 20-patient study will include four months of therapy, then a follow-up interval of exactly the identical duration.
One of those signs is alcoholic hepatitis (AH), which will be “emerging as a top priority sign for DUR-928,” mentioned Arce. Results later this year may come from a Stage 2a open label, multicenter dose escalation research now in progress.
)

None of those study analysts or the researcher’s household has a financial interest in the securities of DURECT Corporation (including, without limitation, any option, right, justify, future, long or short position).


Disclosure:
At February 28, 2019 neither the Company nor its affiliates beneficially own 1% or more of any class of common equity securities of DURECT Corporation.

Members or her of her household own securities of these businesses mentioned in the article: Not one. Members or her of her family are paid by these companies discussed in this article: Not one.
Two ) The following firms discussed in this post are equipping sponsors of Streetwise Reports: DURECT Corp.. Click on here for significant disclosures about sponsor fees.
3) Opinions and opinions expressed are those of their specific experts rather than of Streetwise Reviews or its officers. The information supplied above is for informational purposes only and is not a recommendation to purchase or sell any security.
4) The content does not constitute investment advice. Every reader is invited to talk to her or his respective financial professional and any action a reader takes as a result of information presented here is their own duty. By opening this site, every reader agrees and accepts to Streetwise Reports’ terms of use and complete legal disclaimer. This article isn’t a solicitation for investment. Streetwise Reports does not leave general or specific investment advice and the advice on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, goods, services or securities of any business mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officials, employees or associates of the families, as well as persons interviewed for interviews and articles on the site, might have a long or short position in securities mentioned. Employees, officers, employees or members of the immediate families are prohibited from making purchases and/or sales of these securities in the open market or otherwise from the time of their interview or the decision to compose an article until three business days after the publication of the interview or article. The foregoing prohibition doesn’t apply to articles that in substance only restate previously published firm releases.

Disclosures out of H.C. Wainwright & Co., DURECT Corporation, Earnings Update, March 8, 2019

From The Life Science Report
The research analyst primarily responsible for preparation of this report doesn’t receive compensation that’s based upon any specific investment banking services or trade but is paid based on factors such as total revenue and profitability of the Business, a significant portion of which comes from investment banking solutions.
The most recent news related to the study is from March 7, even when DURECT declared it had progressed the study to Part B, which is for severe AH patients in the 90 mg dose cohort. “The company decided to move forward in light of the “positive benefits in both moderate and severe AH patients who were awarded the 30 mg doses along with the rapid pace of enrollment in Section B, also ” the analyst wrote.
Neither the researcher nor the Firm has some material conflict of interest in of which the researcher knows or has reason to be aware in the time of publication of the study report.

I, Ed Arce and Thomas Yip, cautioned that 1) all of the viewpoints expressed in this report accurately reflect my personal views concerning any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or would be directly or indirectly linked to the particular recommendation or views expressed in this research report; and 3) neither myself nor any members of my family is an officer, director or advisory board member of these companies.

Source: Streetwise Reviews   03/12/2019
This California company anticipates results from clinical trials in liver disease and psoriasis at 2019.
Read what other pros are saying :

Coverage Initiated on Cancer Vaccine Firm

Sourced from: https://www.countingpips.com/2019/03/coverage-initiated-on-cancer-vaccine-firm/

Neither the research analyst nor the Firm has some material conflict of interest in of which the researcher knows or has

The Business does not make a market in Gritstone Oncology, Inc. and Advaxis, Inc. as of the date of this research report.


An H.C. Wainwright & Co. report clarified the reasons for its “bullish view” with this California-based life sciences company.
The Firm or its affiliates did not receive compensation against Gritstone Oncology, Inc. and Advaxis, Inc. for investment banking


Reason to know in the time of publication of the study.

( Companies Mentioned: GRTS:NASDAQ,

The analyst pointed out the Gritstone’s August 2018 deal with bluebird, “clearly one of the greatest cancer cell therapy players,” validates Gritstone’s technologies. The two companies are working with the EDGE AI platform to identify novel tumor goals for cell-based remedies.

Services within twelve months before, but will seek reimbursement from the companies mentioned in this record for investment
banking solutions within three weeks after publication of the research report.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her own securities of the following firms mentioned in the post: None. Members or her of her family are compensated by the following companies discussed in this article: Not one.
Two ) The following firms mentioned in this post are equipping sponsors of Streetwise Reports: None. Click on here for important disclosures about sponsor fees.
3) Opinions and opinions expressed are those of the particular experts rather than of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to purchase or sell any security.
4) This article does not constitute investment advice. Each reader is invited to consult with her or his respective financial pro and any actions a reader takes as a result of information presented here is their own responsibility. By opening this site, each reader accepts and agrees to Streetwise Reports’ terms of use and total authorized disclaimer. This guide isn’t a solicitation for investment. Streetwise Reports does not leave specific or general investment advice and the advice on Streetwise Reports should not be thought of as a recommendation to buy or sell any security. Streetwise Reports doesn’t endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for interviews and articles on the website, may have a long or short position in securities mentioned. Directors, officers, employees or associates of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or from the time of their meeting or the decision to write a post prior to three business days after the publication of the interview or post. The foregoing prohibition does not apply to articles that in material simply restate previously published company releases.

EDGE is an artificial intelligence (AI) system that defines possible tumor neoantigens. It has shown an accuracy that is up to eight times greater than other forecast algorithms, such as MHCflurry and NetMHC.

Source: Streetwise Reports   03/09/2019
None of the study analysts or the research analyst’s household has a financial interest in the securities of Gritstone Oncology, Inc. and Advaxis, Inc. (including, without limitation, any option, right, justify, future, long or short position).
The research analyst primarily responsible for preparation of this report does not receive compensation that’s based upon some specific investment banking solutions or trade but is compensated based on variables such as overall revenue and sustainability of the Company, a significant part of which is derived from investment banking solutions.
As for revenue, H.C. Wainwright projects sales of vaccines to reach $6.5 billion by 2030, Ramakanth suggested. The market potential for GRANITE-001 could be much greater given it could turn into the very first vaccine for use for many cancer types. Together with the $20 million that bluebird bio Inc. (BLUE:NASDAQ) paid for it Gritstone could garner up to $1.2 billion in landmarks, constituting possible additional upside.

Initial clinical data should come this year. Gritstone is now evaluating GRANITE-001 in a Phase 1 research over four cancer forms in conjunction with checkpoint inhibitors: nonsmall cell lung, esophageal, pancreatic and kidney. Findings from this trial are expected in H2/19. “These results would provide an important first-look at how nicely Gritstone’s technological advantage in neoantigen identification and vaccine design is able to translate into clinical efficacy,” noted Ramakanth. If it might, “it could be a major catalyst for the inventory . ”

Subscribe to our FREE newsletter : www.streetwisereports.com/get-news
Disclosure:
Investment Banking Services include, but are not restricted to, acting as a manager/co-manager in the underwriting or placement of securities, or acting as financial adviser, or providing corporate fund or funds markets-related services to a business or among its affiliates or subsidiaries within the previous 12 months.
At a March 7 research note, analyst Swayampakula Ramakanth noted that H.C. Wainwright & Co. initiated coverage on Gritstone Oncology Inc. (GRTS:NASDAQ), a developer of neoantigen-targeting remedies for cancer, using a purchase and a $17 per share price target (versus the current share price of $10.93).
Ramakanth reviewed the firm ’s assets. Gritstone includes two cancer based on its proprietary EDGE technology, which can be GRANITE-001, also a “personalized heterologous prime/boost vaccine,” and SLATE-001, an embryo that is parasitic. Both “have the capability to be best-in-class therapies because of the superior precision of EDGE and the capability to get heterologous prime/boost vaccines to evoke stronger immune reactions compared to the homologous vaccines used by competitors,” Ramakanth commented.